Etiology and prevention of pulmonary complications following beta-mimetic mediated tocolysis

Bader, Anne-Marie; Boudier, E.; Martinez, Claudine; Langer, B.; Sacrez, J; Cherif, Y.; Messier, Marc; Schlaeder, G

doi:10.1016/s0301-2115(98)00105-5

Cited by 12 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alternatively, the activation of b 2 ARs in other cells in the lung may negate the beneficial effects of their activation in the alveolar epithelium. For example, we have recently shown that b 2 -agonist therapy worsens lung inflammation in a murine model of lung injury via engagement of b 2 ARs on macrophages (10). We agree with the authors that additional studies will be needed to distinguish the beneficial effects of b 2 ARs from their unwanted and harmful effects.…”

Section: Reply: B 2 -Agonists and Acute Respiratory Distress Syndromesupporting

confidence: 55%

“…We reported no difference in daily fluid balance in the phase 2 BALTI-1 paper (7) but have no additional unpublished data from BALTI-2 (6) or BALTI-prevention (1) to help shed light on this action. However, we note that when intravenous b 2 -adrenergic agonists were used for tocolysis during pregnancy, they have been associated with reduced sodium, potassium, and water excretion, leading to a reduced hematocrit and intravascular hypervolemia (8,9) and development of maternal pulmonary edema (10).…”

Section: From the Authorsmentioning

confidence: 94%

See 1 more Smart Citation

Reply: Importance of the Kidney, Vessels, and Heart with Administration of β₂ Adrenergic Receptor Agonists in Patients Susceptible to Acute Respiratory Distress Syndrome

Thickett¹,

McAuley²,

Perkins³

2014

Am J Respir Crit Care Med

View full text Add to dashboard Cite

show abstract

Section: Reply: B 2 -Agonists and Acute Respiratory Distress Syndromesupporting

confidence: 55%

Section: From the Authorsmentioning

confidence: 94%

Reply: Importance of the Kidney, Vessels, and Heart with Administration of β₂ Adrenergic Receptor Agonists in Patients Susceptible to Acute Respiratory Distress Syndrome

Thickett¹,

McAuley²,

Perkins³

2014

Am J Respir Crit Care Med

View full text Add to dashboard Cite

show abstract

“…Metabolic sequelae include hypokalamaemia, hyperinsulinaemia and hyperglycaemia [115]. The use of intravenous β 2 -agonists for tocolysis duringpregnancy has been associated with the development of maternal pulmonary oedema [116,117]. Studies investigating this phenomenon in vivo in rabbits and humans found that intravenous injection of β 2 -agonists caused reduced sodium, potassium and water excretion, leading to a reduced haematocrit and intravascular hypervolaemia [118,119].…”

Section: Drug Delivery and Side Effectsmentioning

confidence: 99%

Untitled

et al. 2004

View full text Add to dashboard Cite

25 ALI = acute lung injury; ARDS = acute respiratory distress syndrome; BAL = bronchoalveolar lavage; fMLP = formyl-methionyl-leucyl-phenylalanine; IL = interleukin; KGF = keratinocyte growth factor; LPS = lipopolysaccharide; SP = surfactant protein; TNF = tumour necrosis factor. [1]. Morbidity among survivors is also high, with persistent functional limitation 1 year after discharge preventing over half from returning to work [6].Improvements in general supportive care have contributed toward a trend of decreasing mortality over the past 10 years [7], and recently strategies to reduce the effects of ventilatorassociated lung injury have resulted in an important reduction in mortality [8]. However, as yet no specific pharmacological therapies to target the underlying pathological processes have proved efficacious [9]. Recent in vitro and in vivo animal or human studies suggest that β 2 -agonists -drugs that are well established in the management of patients with chronic bronchitis or asthma -may have an important therapeutic role to play in modulating the initial inflammatory insult and enhancing alveolar fluid clearance in patients with ARDS.The present review discusses the effects of β 2 -agonists on neutrophil functions, on inflammatory mediators, and on epithelial and endothelial functions (Fig. 1). It draws on the extensive experimental and clinical literature on the mechanisms of effects of β 2 -agonists to suggest a potential role for their use as a specific pharmacological intervention in patients with ARDS. ReviewBench-to-bedside review: β β 2 -Agonists and the acute respiratory distress syndrome AbstractThe acute respiratory distress syndrome (ARDS) is a devastating constellation of clinical, radiological and pathological signs characterized by failure of gas exchange and refractory hypoxia. Despite nearly 30 years of research, no specific pharmacological therapy has yet proven to be efficacious in manipulating the pathophysiological processes that underlie this condition. Several in vitro and in vivo animal or human studies suggest a potential role for β 2 -agonists in the treatment of ARDS. These agents have been shown to reduce pulmonary neutrophil sequestration and activation, accelerate alveolar fluid clearance, enhance surfactant secretion, and modulate the inflammatory and coagulation cascades. They are also used widely in clinical practice and are well tolerated in critically ill patients. The present review examines the evidence supporting a role for β 2 -agonists as a specific pharmacological intervention in patients with ARDS.

show abstract

“…Several measures have been suggested to ensure the risk of pulmonary edema is minimized during tocolysis with β‐agonists (19–21). Careful monitoring on an individual basis, as in a high dependency unit, has been advocated during β‐agonist administration.…”

Section: Beta‐agonistsmentioning

confidence: 99%

“…After the report of the Canadian Preterm Labor Investigators the use of b-agonists has been reappraised (18) since which time ritodrine has been removed from use in the USA. Several measures have been suggested to ensure the risk of pulmonary edema is minimized during tocolysis with b-agonists (19)(20)(21). Careful monitoring on an individual basis, as in a high dependency unit, has been advocated during b-agonist administration.…”

Section: Beta-agonistsmentioning

confidence: 99%

An update on the controversies of tocolytic therapy for the prevention of preterm birth

Ingemarsson

Lamont

2003

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

Preterm birth is the major cause of perinatal mortality and morbidity in the developed world. Where there are no contraindications to their use, tocolytics can improve neonatal survival rates by approximately 3% per day between 23 and 27 weeks gestation with a concomitant reduction in morbidity. The ultimate aim of tocolytic therapy is to prolong pregnancy until growth and maturation is complete, but even short-term delay may enable the administration of antepartum glucocorticoids to reduce hyaline membrane disease or to arrange transfer to a center with neonatal intensive care facilities. Both of these have been shown to reduce neonatal mortality and morbidity. Until recently, none of the currently used tocolytics, whether licensed or unlicensed, were developed specifically for the inhibition of preterm labor and consequently, they exhibit various potentially serious side-effects. As a result of the recent licensing of the oxytocin antagonist, atosiban, developed for the treatment of preterm labor and due to its high utero-specificity, obstetricians have experienced an advance in their options for the management of spontaneous preterm labor.

show abstract

Etiology and prevention of pulmonary complications following beta-mimetic mediated tocolysis

Cited by 12 publications

References 8 publications

Reply: Importance of the Kidney, Vessels, and Heart with Administration of β₂ Adrenergic Receptor Agonists in Patients Susceptible to Acute Respiratory Distress Syndrome

Reply: Importance of the Kidney, Vessels, and Heart with Administration of β₂ Adrenergic Receptor Agonists in Patients Susceptible to Acute Respiratory Distress Syndrome

Untitled

An update on the controversies of tocolytic therapy for the prevention of preterm birth

Contact Info

Product

Resources

About

Etiology and prevention of pulmonary complications following beta-mimetic mediated tocolysis

Cited by 12 publications

References 8 publications

Reply: Importance of the Kidney, Vessels, and Heart with Administration of β2 Adrenergic Receptor Agonists in Patients Susceptible to Acute Respiratory Distress Syndrome

Reply: Importance of the Kidney, Vessels, and Heart with Administration of β2 Adrenergic Receptor Agonists in Patients Susceptible to Acute Respiratory Distress Syndrome

Untitled

An update on the controversies of tocolytic therapy for the prevention of preterm birth

Contact Info

Product

Resources

About

Reply: Importance of the Kidney, Vessels, and Heart with Administration of β₂ Adrenergic Receptor Agonists in Patients Susceptible to Acute Respiratory Distress Syndrome

Reply: Importance of the Kidney, Vessels, and Heart with Administration of β₂ Adrenergic Receptor Agonists in Patients Susceptible to Acute Respiratory Distress Syndrome